Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential Trastuzumab Rezetecan and Pyrotinib-based Maintenance in Advanced HER2+ Breast Cancer
NCT07766772Phase 2Not yet recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Sep 2026
- Primary completion
- Dec 2031
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab rezetecan, pyrotinib in breast cancer, sponsored by Fujian Medical University Cancer Hospital. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
trastuzumab rezetecanpyrotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07766772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07766772.